Market Overview

What The Street...And The Crowd Are Watching At Amgen Before Earnings


Amgen, Inc. (NASDAQ: AMGN) is scheduled to report earnings on Tuesday afternoon, and taking a look at Estimize might provide a better idea of what to expect.

According to the site, Wall Street analysts are expecting EPS of $2.07 on revenue of $4.923 billion. However, Estimize users are slightly more bullish, projecting -- on average -- EPS of $2.13, on revenue of $4.978 billion.

The chart below illustrates these views.

Amgen did not provide any guidance for the first quarter. However, for the full year, the company expects EPS of $9.05 to $9.40 on revenues of $20.8 billion to $21.3 billion.

It's also possible to view how estimates have changed over time. While users have become increasingly optimistic, Wall Street analysts have been losing confidence over the past few days, after three months of growing expectations.

5 Questions To Ask

In a recent article, Investopedia said they expect another estimate-beating quarter at Amgen and propose 5 questions to ask:

1)   Was it price or volume driving sales growth?

2)   “Did negative currency translation play a role?”

3)   Are the cost-cutting initiatives hitting the mark?

4)   Did Kyprolis sales improve?

5)   Is a split or break-up in the company’s plans?

Posted-In: EstimizeBiotech Health Care Previews Trading Ideas General


Related Articles (AMGN)

View Comments and Join the Discussion!

The Wheels Come Off Harley-Davidson

Google Isn't The Only Company In The EU Firing Line